Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels

  • Authors:
    • Yuan Jian
    • Wen Gao
    • Chuanying Geng
    • Huixing Zhou
    • Yun Leng
    • Yanchen Li
    • Wenming Chen
  • View Affiliations

  • Published online on: June 30, 2017     https://doi.org/10.3892/ol.2017.6502
  • Pages: 3243-3248
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The mechanism of the anti-myeloma effect of the immunomodulatory drug lenalidomide relies upon the binding of lenalidomide or an analogue to cereblon (CRBN) ubiquitin ligase, which inhibits it and results in the degradation of Ikaros-family zinc finger proteins 1 and 3 (IKZF1 and IKZF3). To determine whether the traditional Chinese medicine arsenic trioxide, could potentiate sensitivity of multiple myeloma (MM) cells to lenalidomide and identify the mechanism by which this happens, the present study investigated how arsenic trioxide affected CRBN on MM cell lines and examined the anti-myeloma effect and mechanism in the combination of arsenic trioxide and lenalidomide. The present study revealed that arsenic trioxide upregulates the transcription and protein levels of CRBN, the anti-myeloma target of lenalidomide, thus potentiating the sensitivity of multiple myeloma cells to lenalidomide and enhancing the lenalidomide-dependent degradation of IKZF1 and IKZF3. The results of the present study indicate that clinical trials of this combination therapy could take place within the near future, with the aim of improving MM patient outcome.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jian Y, Gao W, Geng C, Zhou H, Leng Y, Li Y and Chen W: Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncol Lett 14: 3243-3248, 2017.
APA
Jian, Y., Gao, W., Geng, C., Zhou, H., Leng, Y., Li, Y., & Chen, W. (2017). Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncology Letters, 14, 3243-3248. https://doi.org/10.3892/ol.2017.6502
MLA
Jian, Y., Gao, W., Geng, C., Zhou, H., Leng, Y., Li, Y., Chen, W."Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels". Oncology Letters 14.3 (2017): 3243-3248.
Chicago
Jian, Y., Gao, W., Geng, C., Zhou, H., Leng, Y., Li, Y., Chen, W."Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels". Oncology Letters 14, no. 3 (2017): 3243-3248. https://doi.org/10.3892/ol.2017.6502